Dihexyldiphenyl Ether Disulfonate is a pharmacologically or chemically characterised molecule whose biological activity, physicochemical properties, and toxicological profile have been evaluated to establish its health-based exposure limits for pharmaceutical manufacturing. Its molecular structure—defined by NMR, IR, mass spectrometry, and elemental analysis—determines receptor binding, metabolic transformation pathways, and chemical reactivity relevant to both therapeutic utility and toxicological risk assessment. ADME parameters including oral bioavailability, plasma protein binding, volume of distribution, and metabolic clearance inform toxicokinetic modelling applied during PDE derivation.
PDE derivation for Dihexyldiphenyl Ether Disulfonate applies the composite uncertainty factor methodology: F1 accounts for interspecies pharmacokinetic and pharmacodynamic differences (default 12 for rat-to-human, refinable with toxicokinetic AUC bridging data), F2 covers intraspecies variability in the human population including sensitive subgroup
